When there is still persistent intraretinal or subretinal fluid or recurrent exudation during examination with optical coherence tomography even after 3 or more treatments with intravitreal anti-VEGF antibody, these patients are classified as refractory or resistant neovascular (wet) AMD groups and need to obtain switch therapy to other anti-VEGF drugs [22], resulting in improvement of best-corrected visual acuity and the regression of retinal edema and pigment epithelial detachment [23,24]. This evidence concerns the gene VEGFA and age-related macular degeneration.